Related Experiment Videos
The macrophagic activity of patients affected by pneumonia or chronic obstructive pulmonary disease
F Ferrara1, D D'Adda, M Falchi
1Department of Pharmacology, Chemotherapy and Toxicology, Faculty of Medicine, University of Milan, Italy.
Abstract:
The function of alveolar macrophages (AMS) in patients with pneumonia (n = 7) (Group A) and chronic obstructive pulmonary disease (COPD) (n = 11) (Group B) was investigated by evaluating the rate of phagocytosis and of the intracellular killing. A control group of healthy subjects (n = 8) was also included. Phagocytosis frequency (PHF), phagocytosis index (PHI) and intracellular killing towards Candida albicans were then evaluated. PHF and PHI were found to be significantly (p < 0.05) lower in Group B patients than in the control group, while intracellular killing showed a behaviour similar to controls. PHF and PHI values observed in the patients of Group A and in the control group did not show any significant difference; the intracellular killing rate proved on the contrary to be significantly (p < 0.05) lower than that observed in the controls.
Insights
Alveolar macrophages (AMS) show reduced phagocytosis in chronic obstructive pulmonary disease (COPD) patients. Pneumonia patients had impaired intracellular killing, but phagocytosis remained normal.
Area of Science:
- Immunology
- Pulmonology
- Cell Biology
Background:
- Alveolar macrophages (AMS) are crucial immune cells in the lungs.
- Their function can be altered in respiratory diseases like pneumonia and COPD.
- Evaluating AMS phagocytosis and killing is key to understanding lung immunity.
Purpose of the Study:
- To investigate the phagocytic and intracellular killing functions of alveolar macrophages (AMS).
- To compare AMS function in patients with pneumonia and COPD against healthy controls.
Main Methods:
- Assessed phagocytosis frequency (PHF) and phagocytosis index (PHI) of AMS.
- Evaluated intracellular killing capacity of AMS towards Candida albicans.
- Compared results between pneumonia patients (Group A), COPD patients (Group B), and healthy controls.
Main Results:
- COPD patients (Group B) exhibited significantly lower PHF and PHI compared to controls.
- Intracellular killing in COPD patients was similar to controls.
- Pneumonia patients (Group A) showed no significant difference in PHF and PHI versus controls.
- Pneumonia patients demonstrated significantly lower intracellular killing rates than controls.
Conclusions:
- Alveolar macrophage phagocytosis is impaired in COPD.
- Pneumonia is associated with reduced intracellular killing capacity of alveolar macrophages.
- These findings highlight distinct functional deficits of AMS in different lung diseases.